Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy MacroGenics Inc (MGNX)?

Page 1 of 2

Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap stocks. There is little or no publicly-available information at all on some of these small companies, which makes it hard for an individual investor to pin down a winner within the small-cap space. However, hedge funds and other big asset managers can do the due diligence and analysis for you instead, thanks to their highly-skilled research teams and vast resources to conduct an appropriate evaluation process. Looking for potential winners within the small-cap galaxy of stocks? We believe following the smart money is a good starting point.

MacroGenics Inc (NASDAQ:MGNX) was in 21 hedge funds’ portfolios at the end of September. MacroGenics Inc (NASDAQ:MGNX) investors should be aware of an increase in activity from the world’s largest hedge funds in recent months. There were 20 hedge funds in our database with MacroGenics Inc (NASDAQ:MGNX) positions at the end of the previous quarter. At the end of this article, we will also compare MacroGenics Inc (NASDAQ:MGNX) to other stocks, including Hercules Technology Growth Capital Inc (NYSE:HTGC), Rofin-Sinar Technologies (NASDAQ:RSTI), and ADTRAN, Inc. (NASDAQ:ADTN) to get a better sense of its popularity.

Follow Macrogenics Inc (NASDAQ:MGNX)
Trade (NASDAQ:MGNX) Now!

To most market participants, hedge funds are seen as worthless, old financial vehicles of yesteryear. While there are over 8000 funds in operation today, our experts look at the crème de la crème of this group, approximately 700 funds. These hedge fund managers watch over the lion’s share of the hedge fund industry’s total capital, and by watching their unrivaled investments, Insider Monkey has brought to light a number of investment strategies that have historically exceeded the broader indices. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points per year for a decade in their back tests.

With all of this in mind, we’re going to view the recent action regarding MacroGenics Inc (NASDAQ:MGNX).

How have hedgies been trading MacroGenics Inc (NASDAQ:MGNX)?

Heading into Q4, a total of 21 of the hedge funds tracked by Insider Monkey were long this stock, an increase of 5% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of noteworthy hedge fund managers who were boosting their stakes significantly (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Point72 Asset Management, managed by Steve Cohen, holds the most valuable position in MacroGenics Inc (NASDAQ:MGNX). Point72 Asset Management has a $54.2 million position in the stock, comprising 0.4% of its 13F portfolio. On Point72 Asset Management’s heels is John Griffin of Blue Ridge Capital, with a $28.9 million position; 0.3% of its 13F portfolio is allocated to the stock. Remaining peers with similar optimism consist of Dmitry Balyasny’s Balyasny Asset Management, James E. Flynn’s Deerfield Management, and Tiger Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!